NCT01509911 - A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

October 31, 2016

Study Completion Date

January 31, 2017

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG

TL-118

TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles.

DRUG

Gemcitabine

Monthly cycles of 3 weekly treatments a month and one week off of treatment

Trial Locations (10)

10601

White Plains Hospital, White Plains

30322

Emory Clinic, Atlanta

38100

Hillel Yaffe Medical Center, Hadera

70300

Assaf Harofe Medical Center, Ẕerifin

Unknown

HaEmek Medical Center, Afula

Soroka Medical Center, Beersheba

Rambam Medical Center, Haifa

Hadassah Medical Center, Jerusalem

Sheba Medical Center, Ramat Gan

Sourasky Medical Center, Tel Aviv